CCTG

BR.31

NCT02273375

BR.31

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

Adjuvant

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

PD-1, PD-L1, EGFR, ALK

Investigational

Product

Durvalumab (MEDI4736)

Anti-PD-L1 Monoclonal Antibody (i.v.)

Treatment Arms

o Experimental: MEDI4736

o Placebo Comparator: Placebo